

Patient Reported Outcomes Burdens and Experiences Study

Health status of people living with non-severe hemophilia

ISTH Annual Meeting 2019, Melbourne

Chatree Chai-Adisaksopha¹, Mark W Skinner², Randall Curtis³, Neil Frick⁴, Michael Nichol⁵ Declan Noone⁶, Brian O'Mahony⁶, David Page⁷, Jeff Stonebraker⁸, Lehana Thabane¹, Mark Crowther¹ and Alfonso Iorio¹

¹McMaster University, ²Institute for Policy Development Ltd., Washington, US ³Factor VIII Computing, Berkeley, US ³National Hemophilia Foundation, New York City, US ⁵School of Policy and Planning Development, University of Southern California, Los Angeles, US ⁶Irish Haemophilia Society, Dublin, Ireland,⁷Canadian Hemophilia Society, Montreal, Canada ⁸Poole College of Management, North Carolina State University, Raleigh, US



Disclosures

• No potential conflicts of interest

Enhancing the direct patient voice in healthcare decision-making.

PORG Ltd 2017




Background

- Non-severe hemophilia
 - Moderate hemophilia: reduced factor level of 1-5 IU/dL
 - Mild hemophilia: reduced factor level of <40 IU/dL
- Clinical manifestations of non-severe hemophilia
 - Rare spontaneous bleeding
 - Excessive bleeding after surgical procedures or trauma

WFH 2012. J Thromb Haemost. 2018 Dec;16(12):2530-2533. Blood Transfus 2018; 16: 535-44.

PROBE

Life expectancy of PWH compared to non-hemophilia males (UK)



Blood. 2007;110:815-825



Knowledge gap

• Limited data on the health status of people living with non-severe hemophilia



Objective

• To investigate the health status of people living with non-severe hemophilia comparing with people without bleeding disorders

PROBE

Methods-participant enrollment and data collection

- Participants were enrolled through patient organizations from 2016-2017
- Inclusion criteria
 - PWH (non-severe) and people without bleeding disorders
 - Age> 10 years
 - To be able to complete the questionnaire by themselves
- Study procedure and data collection
 - Participants were instructed to answer the questionnaire either paper- or web-based version
 - All questionnaires were collected by participants organizations then transferred to McMaster University for data management



Methods-PROBE questionnaire

- PROBE is a patient-lead research initiative with the main objective to develop a standardised questionnaire to assess health status in PWH
- PROBE questionnaire (29 questions in 3 major domains)
 - General health problems
 - Hemophilia-related problems
 - Health-related quality of life
- PROBE has been validated in both PWH and participants without bleeding disorders

Chai-Adisaksopha C, et al. BMJ Open 2018;8:e021900.

PROBE

PROBE items on pain assessment

- During the past 12 months, have you experienced acute pain?
 - Yes
 - No

If yes, when did your acute pain occur? (Please check all that apply)

Walking

Stair climbing

Nighttime (such as waking you up/keeping you awake)

Resting

Weight bearing

Playing (including playing with children) or participating in sports / $\ensuremath{\mathsf{exercising}}$

After falling or a trauma

Other (Describe): _____

If yes, does your acute pain interfere with any of the following? (Please check all that apply)

General activity Mood Walking ability Normal work (including both work outside the home and housework) Attending school Relations with others Sleep Enjoyment of life Playing (including playing with children) or participating in sports / exercising Lifting Other (Describe): ______



Health-related quality of life

• EQ-5D-5L

Work or school life

- Work or school status
- Sick days per year



Statistical analysis

- 1:1 age and sex matched
- Descriptive data were reported as a proportion and mean (standard deviation) as appropriate.
- Study outcomes
 - General health problems
 - Health-related quality of life
 - Work and school life


PROBE

Characteristics of participants


Characteristics	Non-severe hemophilia (n=183)	No bleeding disorder (n=183)
Age (mean, SD)	44.7 (± 17.4)	45.7 (± 14.4)
Sex (male, %)	153 (83.6)	153 (83.6)
Geographical region, n(%)		
Africa	2 (1.1)	0 (1.1)
Western Pacific	48 (26.2)	40 (21.9)
South America	51 (27.9)	47 (25.7)
• Europe	56 (30.6)	38 (20.8)
North America	26 (14.2)	58 (31.7)
Disease status		
Hemophilia A	144 (78.7)	N/A
Hemophilia B	39 (21.3)	



Health related problems




Experiencing problems related to health



Using mobility aids



Difficulty with activities of daily living




Enhancing the direct patient voice in healthcare decision-making.

PORG Ltd 2017




Health related problems






EQ-5D-5L on anxiety/depression (%)






Work and school life





Work and school life






Work and school life (continued)

• Sick days per year

Sick days per year	Non-severe hemophilia (n=183)	No bleeding disorder (n=183)	P-value
Median	7	0	<0.001
(interquartile range)	(0-25)	(0-3)	
Mean	44.9	3.7	<0.001
(SD)	(8.7)	(1.5)	



Overall health status assessed by PROBE score (Higher score indicates better health status)



Enhancing the direct patient voice in healthcare decision-making.

PORG Ltd 2017



Conclusions

- Compared to participants without bleeding disorders, people with non-severe hemophilia had much worse health status
 - Health-related problems
 - Work and school life
 - Health-related quality of life
- Non-severe hemophilia is not a benign disease.



Conclusions

- Clinical outcomes, such as, annualized bleeding rate or mortality are less sensitive to detect health status in theses populations.
- We encourage investigators and clinicians to use a patientreported outcome tool for assessing the health status of PWH



Collaborating Patient Organizations

- Fundación de la Hemofilia (Argentina) Cordoba Chapter
- Hemophilia Foundation Australia
- Federaçao Brasileira de Hemofilia (Brazil)
- Canadian Hemophilia Society
- Association Française des Hémophiles (France)
- Deutsche Hämophiliegesellschaft (Germany)
- Magyar Hemofilia Egyesulet (Hungary)
- Irish Haemophilia Society
- Federazione delle Associazioni Emofilici (Italy)
- National Hemophilia Network of Japan

- Federación de Hemofilia de la República Mexicana (Mexico)
- Nederlandse Vereniging van Hemofilie-Patiënten (The Netherlands)
- Haemophilia Foundation of New Zealand
- Haemophilia Foundation of Nigeria
- Polish Hemophilia Society
- v) Federación Española de Hemofilia (Spain)
 - The Haemophilia Society (United Kingdom)
 - National Hemophilia Foundation (US)
 - Asociación Venezolana para la Hemofilia (Venezuela)
 - Vietnamese Hemophilia Association



Acknowledgements

- PROBE is an independent investigator led research project with grant / research support from:
 - Bayer
 - Bioverative
 - CSL Behring
 - Novo Nordisk (HERO)
 - Roche
 - Shire
 - Sobi
- Project support: National Hemophilia Foundation (US)



For more information

If you have questions or would like more information about PROBE you may directly contact the PROBE investigator team:

- Mark W. Skinner, Principal Investigator
 - Phone: +1.202.253.8342
- Sasha Pastarnak, Research Data Manager
 - Phone: +1.347.9724250
- E-mail: info@probestudy.org
- Web: www.probestudy.org